Acelyrin, Inc. Stock price

Equities

SLRN

US00445A1007

Biotechnology & Medical Research

Market Closed - Nasdaq 03:59:55 2024-02-23 pm EST 5-day change 1st Jan Change
7.4 USD -1.60% Intraday chart for Acelyrin, Inc. -11.38% -0.80%
Sales 2023 * - Sales 2024 * - Capitalization 721M
Net income 2023 * -386M Net income 2024 * -410M EV / Sales 2023 * -
Net cash position 2023 * 382M Net Debt 2024 * 49.58M EV / Sales 2024 * -
P/E ratio 2023 *
-1.04 x
P/E ratio 2024 *
-1.76 x
Employees 108
Yield 2023 *
-
Yield 2024 *
-
Free-Float 72.25%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.60%
1 week-11.38%
Current month-2.89%
1 month+6.78%
3 months-15.33%
6 months-72.93%
Current year-0.80%
More quotes
1 week
7.29
Extreme 7.29
8.72
1 month
6.98
Extreme 6.98
8.72
Current year
5.70
Extreme 5.7
8.72
1 year
5.70
Extreme 5.7
29.88
3 years
5.70
Extreme 5.7
29.88
5 years
5.70
Extreme 5.7
29.88
10 years
5.70
Extreme 5.7
29.88
More quotes
Managers TitleAgeSince
Founder 57 20-07-26
Director of Finance/CFO 52 22-06-30
Chief Tech/Sci/R&D Officer 66 21-04-30
Members of the board TitleAgeSince
Director/Board Member 67 20-09-30
Director/Board Member 60 21-04-30
Director/Board Member 61 21-10-31
More insiders
Date Price Change Volume
24-02-23 7.41 -1.46% 501,403
24-02-22 7.52 -1.57% 1,122,565
24-02-21 7.64 0.00% 620,650
24-02-20 7.64 -8.50% 1,042,238
24-02-16 8.35 +10.89% 3,238,179

Delayed Quote Nasdaq, February 23, 2024 at 03:59 pm EST

More quotes
ACELYRIN, INC. is a late-stage clinical biopharmaceutical company. The Company is focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. Its initial focus is on the treatment of diseases with pathology related to excess activation of the immune system. The Company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit anti-interleukin (IL)-17A with high potency through tight binding affinity and the potential for robust tissue penetration due to its small molecular size, about one-tenth the size of a monoclonal antibody. It is also advancing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R). Lonigutamab has shown high potency against IGF-1R in both binding and functional laboratory assays. In addition, the Company is developing SLRN-517, which is a fully human IgG1 monoclonal antibody targeting c-KIT.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
7.41 USD
Average target price
23.67 USD
Spread / Average Target
+219.39%
Consensus
1st Jan change Capi.
-0.80% 721 M $
+5.71% 111 B $
+11.72% 105 B $
+9.93% 24 182 M $
-10.96% 22 338 M $
-26.36% 21 352 M $
-6.59% 19 088 M $
-14.01% 16 173 M $
+1.84% 13 352 M $
+41.59% 12 772 M $
Bio Therapeutic Drugs
  1. Stock
  2. Equities
  3. Stock Acelyrin, Inc. - Nasdaq
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer